Portal de Periódicos da CAPES

Effects of growth factors and cytokines on osteoblast differentiation

2006; Wiley; Volume: 41; Issue: 1 Linguagem: Inglês

10.1111/j.1600-0757.2006.00161.x

1600-0757

Francis J. Hughes, Wendy Turner, Georgios N. Belibasakis, Gianluca Martuscelli,

dental development and anomalies

Periodontology 2000Volume 41, Issue 1 p. 48-72 Effects of growth factors and cytokines on osteoblast differentiation Francis J. Hughes, Francis J. HughesSearch for more papers by this authorWendy Turner, Wendy TurnerSearch for more papers by this authorGeorgios Belibasakis, Georgios BelibasakisSearch for more papers by this authorGianluca Martuscelli, Gianluca MartuscelliSearch for more papers by this author Francis J. Hughes, Francis J. HughesSearch for more papers by this authorWendy Turner, Wendy TurnerSearch for more papers by this authorGeorgios Belibasakis, Georgios BelibasakisSearch for more papers by this authorGianluca Martuscelli, Gianluca MartuscelliSearch for more papers by this author First published: 10 May 2006 https://doi.org/10.1111/j.1600-0757.2006.00161.xCitations: 172Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL References 1 Abbas S, Zhang YH, Clohisy JC, Abu-Amer Y. Tumor necrosis factor-alpha inhibits pre-osteoblast differentiation through its type-1 receptor. Cytokine 2003: 22: 33– 41. 2 Ahdjoudj S, Fromigue O, Marie PJ. Plasticity and regulation of human bone marrow stromal osteoprogenitor cells: potential implication in the treatment of age-related bone loss. Histol Histopathol 2004: 19: 151– 157. 3 Ahn J, Serrano de la Pena L, Shore EM, Kaplan FS. Paresis of a bone morphogenetic protein-antagonist response in a genetic disorder of heterotopic skeletogenesis. J Bone Joint Surg Am 2003: 85-A: 667– 674. 4 Allan EH, Ho PW, Umezawa A, Hata J, Makishima F, Gillespie MT, Martin TJ. Differentiation potential of a mouse bone marrow stromal cell line. J Cell Biochem 2003: 90: 158– 169. 5 Alliston T, Choy L, Ducy P, Karsenty G, Derynck R. TGF-beta-induced repression of CBFA1 by Smad3 decreases cbfa1 and osteocalcin expression and inhibits osteoblast differentiation. Embo J 2001: 20: 2254– 2272. 6 Annes JP, Munger JS, Rifkin DB. Making sense of latent TGFbeta activation. J Cell Sci 2003: 116: 217– 224. 7 Antosz ME, Bellows CG, Aubin JE. Effects of transforming growth factor ß and epidermal growth factor on cell proliferation and the formation of bone nodules in isolated fetal rat calvaria cells. J Cell Physiol 1989: 140: 386– 395. 8 Anusaksathien O, Webb SA, Jin QM, Giannobile WV. Platelet-derived growth factor gene delivery stimulates ex vivo gingival repair. Tissue Eng 2003: 9: 745– 756. 9 Arend WP, Welgus HG, Thompson RC, Eisenberg SP. Biological properties of recombinant human monocyte-derived interleukin 1 receptor antagonist. J Clin Invest 1990: 85: 1694– 1697. 10 Asahina I, Sampath TK, Hauschka PV. Human osteogenic protein-1 induces chondroblastic, osteoblastic, and/or adipocytic differentiation of clonal murine target cells. Exp Cell Res 1996: 222: 38– 47. 11 Aubin JE. Advances in the osteoblast lineage. Biochem Cell Biol 1998: 76: 899– 910. 12 Auron PE. The interleukin 1 receptor: ligand interactions and signal transduction. Cytokine Growth Factor Rev 1998: 9: 221– 237. 13 Bain G, Muller T, Wang X, Papkoff J. Activated beta-catenin induces osteoblast differentiation of C3H10T1/2 cells and participates in BMP2 mediated signal transduction. Biochem Biophys Res Commun 2003: 301: 84– 91. 14 Baldock PA, Eisman JA. Genetic determinants of bone mass. Curr Opin Rheumatol 2004: 16: 450– 456. 15 Balemans W, Van Hul W. Identification of the disease-causing gene in sclerosteosis – discovery of a novel bone anabolic target? J Musculoskelet Neuronal Interact 2004: 4: 139– 142. 16 Beck GR, Jr, Zerler B, Moran E. Gene array analysis of osteoblast differentiation. Cell Growth Differ 2001: 12: 61– 83. 17 Bellido T, Borba VZ, Roberson P, Manolagas SC. Activation of the Janus kinase/STAT (signal transducer and activator of transcription) signal transduction pathway by interleukin-6-type cytokines promotes osteoblast differentiation. Endocrinology 1997: 138: 3666– 3676. 18 Beresford JN, Bennett JH, Devlin C, Leboy PS, Owen ME. Evidence for an inverse relationship between the differentiation of adipocytic and osteogenic cells in rat marrow stromal cell cultures. J Cell Sci 1992: 102: 341– 351. 19 Bertolini DR, Nedwin GE, Bringman TS, Smith DD, Mundy GR. Stimulation of bone resorption and inhibition of bone formation in vitro by human tumour necrosis factors. Nature 1986: 319: 516– 518. 20 Boabaid F, Gibson CW, Kuehl MA, Berry JE, Snead ML, Nociti FH Jr, Katchburian E, Somerman MJ. Leucine-rich amelogenin peptide: a candidate signaling molecule during cementogenesis. J Periodontol 2004: 75: 1126– 1136. 21 Boyce BF, Xing L, Franzoso G, Siebenlist U. Required and nonessential functions of nuclear factor-kappa B in bone cells. Bone 1999: 25: 137– 139. 22 Brandstrom H, Jonsson KB, Vidal O, Ljunghall S, Ohlsson C, Ljunggren O. Tumor necrosis factor-alpha and -beta upregulate the levels of osteoprotegerin mRNA in human osteosarcoma MG-63 cells. Biochem Biophys Res Commun 1998: 248: 454– 457. 23 Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, Capparelli C, Scully S, Tan HL, Xu W, Lacey DL, Boyle WJ, Simonet WS. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 1998: 12: 1260– 1268. 24 Burger EH, Klein-Nulend J, Smit TH. Strain-derived canalicular fluid flow regulates osteoclast activity in a remodelling osteon – a proposal. J Biomech 2003: 36: 1453– 1459. 25 Canalis E. Interleukin-1 has independent effects on deoxyribonucleic acid and collagen synthesis in cultures of rat calvariae. Endocrinology 1986: 118: 74– 81. 26 Canalis E. Insulin-like growth factors and osteoporosis. Bone 1997: 21: 215– 216. 27 Canalis E, Gabbitas B. Bone morphogenetic protein 2 increases insulin-like growth factor I and II transcripts and polypeptide levels in bone cell cultures. J Bone Miner Res 1994: 9: 1999– 2005. 28 Canalis E, Raisz LG. Effect of fibroblast growth factor on cultured fetal rat calvaria. Metabolism 1980: 29: 108– 114. 29 Canalis E, Centrella M, McCarthy T. Effects of basic fibroblast growth factor on bone formation in vitro. J Clin Invest 1988: 81: 1572– 1577. 30 Canalis E, Economides AN, Gazzerro E. Bone morphogenetic proteins, their antagonists, and the skeleton. Endocr Rev 2003: 24: 218– 235. 31 Canalis E, Deregowski V, Pereira RC, Gazzerro E. Signals that determine the fate of osteoblastic cells. J Endocrinol Invest 2005: 28: 3– 7. 32 Carlson NE, Roach RB Jr. Platelet-rich plasma: clinical applications in dentistry. J Am Dent Assoc 2002: 133: 1383– 1386. 33 Carpentier I, Beyaert R. TRAF1 is a TNF inducible regulator of NF-kappaB activation. FEBS Lett 1999: 460: 246– 250. 34 Celil AB, Campbell PG, Datto M, Wang XF, Hollinger JO, Selvamurugan N, Kwok S, Alliston T, Reiss M, Partridge NC, Hassel S, Schmitt S, Hartung A, Roth M, Nohe A, Petersen N, Ehrlich M, Henis YI, Sebald W, Knaus P, Lee KS, Hong SH, Bae SC, Lai CF, Cheng SL. BMP-2 and insulin-like growth factor-I mediate Osterix (Osx) expression in human mesenchymal stem cells via the MAPK and protein kinase D signaling pathways. J Biol Chem 2005: 280: 31353– 31359. 35 Centrella M, McCarthy TL, Canalis E. Transforming growth factor beta is a bifunctional regulator of replication and collagen synthesis in osteoblast-enriched cell cultures from fetal rat bone. J Biol Chem 1987: 262: 2869– 2874. 36 Centrella M, Horowitz MC, Wozney JM, McCarthy TL. Transforming growth factor-beta gene family members and bone. Endocr Rev 1994: 15: 27– 39. 37 Cerny R, Slaby I, Hammarstrom L, Wurtz T. A novel gene expressed in rat ameloblasts codes for proteins with cell binding domains. J Bone Miner Res 1996: 11: 883– 891. 38 Chaudhary LR, Spelsberg TC, Riggs BL. Production of various cytokines by normal human osteoblast-like cells in response to interleukin-1 beta and tumor necrosis factor-alpha: lack of regulation by 17 beta-estradiol. Endocrinology 1992: 130: 2528– 2534. 39 Chen TL, Bates RL, Dudley A, Hammonds R Jr, Amento EP. Bone morphogenetic protein-2b stimulation of growth and osteogenic phenotypes in rat osteoblast-like cells: comparison with TGF-beta 1. J Bone Miner Res 1991: 6: 1387– 1393. 40 Cho MI, Lin WL, Genco RJ. Platelet-derived growth factor-modulated guided tissue regenerative therapy. J Periodontol 1995: 66: 522– 530. 41 Colotta F, Re F, Muzio M, Bertini R, Polentarutti N, Sironi M, Giri JG, Dower SK, Sims JE, Mantovani A. Interleukin-1 type II receptor: a decoy target for IL-1 that is regulated by IL-4. Science 1993: 261: 472– 475. 42 Conget PA, Allers C, Minguell JJ. Identification of a discrete population of human bone marrow-derived mesenchymal cells exhibiting properties of uncommitted progenitors. J Hematother Stem Cell Res 2001: 10: 749– 758. 43 Cornish J, Gillespie MT, Callon KE, Horwood NJ, Moseley JM, Reid IR. Interleukin-18 is a novel mitogen of osteogenic and chondrogenic cells. Endocrinology 2003: 144: 1194– 1201. 44 De Crombrugghe B, Lefebvre V, Behringer RR, Bi W, Murakami S, Huang W. Transcriptional mechanisms of chondrocyte differentiation. Matrix Biol 2000: 19: 389– 394. 45 Crookston KP, Webb DJ, Lamarre J, Gonias SL. Binding of platelet-derived growth factor-BB and transforming growth factor-beta 1 to alpha 2-macroglobulin in vitro and in vivo: comparison of receptor-recognized and non-recognized alpha 2-macroglobulin conformations. Biochem J 1993: 293 (Pt 2): 443– 450. 46 Dabovic B, Levasseur R, Zambuto L, Chen Y, Karsenty G, Rifkin DB. Osteopetrosis-like phenotype in latent TGF-beta binding protein 3 deficient mice. Bone 2005: 37: 25– 31. 47 Dai JC, He P, Chen X, Greenfield EM. TNFalpha and PTH utilize distinct mechanisms to induce IL-6 and RANKL expression with markedly different kinetics. Bone 2006: 38: 509– 520. 48 Davideau JLSCTIBA. EGF receptor expression in mineralized tissues: an in situ hybridization and immunocytochemical investigation in rat and human mandibles. Conn Tissue Res 1995: 32: 47– 53. 49 Debiais F, Hott M, Graulet AM, Marie PJ. The effects of fibroblast growth factor-2 on human neonatal calvaria osteoblastic cells are differentiation stage specific. J Bone Miner Res 1998: 13: 645– 654. 50 Dedhar S, Mitchell MD, Pierschbacher MD. The osteoblast-like differentiated phenotype of a variant of MG-63 osteosarcoma cell line correlated with altered adhesive properties. Conn Tissue Res 1989: 20: 49– 61. 51 Dennis JE, Carbillet JP, Caplan AI, Charbord P. The STRO-1+ marrow cell population is multipotential. Cells Tissues Organs 2002: 170: 73– 82. 52 Dinarello CA. Interleukin-1 and its biologically related cytokines. Adv Immunol 1989: 44: 153– 205. 53 Dinarello CA. Interleukin-18. Methods 1999: 19: 121– 132. 54 Ducy P, Desbois C, Boyce B, Pinero G, Story B, Dunstan C, Smith E, Bonadio J, Goldstein S, Gundberg C, Bradley A, Karsenty G. Increased bone formation in osteocalcin-deficient mice. Nature 1996: 382: 448– 452. 55 Ducy P, Zhang R, Geoffroy V, Ridall AL, Karsenty G. Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation. Cell 1997: 89: 747– 754. 56 Ducy P, Zhang R, Geoffroy V, Ridall A, Karsenty G. Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation. Cell 1997: 89: 677– 680. 57 Ellies LG, Aubin JE. Temporal sequence of interleukin 1 alpha-mediated stimulation and inhibition of bone formation by isolated fetal rat calvaria cells in vitro. Cytokine 1990: 2: 430– 437. 58 Erices A, Conget P, Rojas C, Minguell JJ. Gp130 activation by soluble interleukin-6 receptor/interleukin-6 enhances osteoblastic differentiation of human bone marrow-derived mesenchymal stem cells. Exp Cell Res 2002: 280: 24– 32. 59 Ernst M, Jenkins BJ. Acquiring signalling specificity from the cytokine receptor gp130. Trends Genet 2004: 20: 23– 32. 60 Firestein GS. Evolving concepts of rheumatoid arthritis. Nature 2003: 423: 356– 361. 61 Franceschi RT, Wang D, Krebsbach PH, Rutherford RB. Gene therapy for bone formation: in vitro and in vivo osteogenic activity of an adenovirus expressing BMP7. J Cell Biochem 2000: 78: 476– 486. 62 Franchimont N, Gangji V, Durant D, Canalis E. Interleukin-6 with its soluble receptor enhances the expression of insulin-like growth factor-I in osteoblasts. Endocrinology 1997: 138: 5248– 5255. 63 Franchimont N, Durant D, Canalis E. Interleukin-6 and its soluble receptor regulate the expression of insulin-like growth factor binding protein-5 in osteoblast cultures. Endocrinology 1997: 138: 3380– 3386. 64 Franchimont N, Durant D, Rydziel S, Canalis E. Platelet-derived growth factor induces interleukin-6 transcription in osteoblasts through the activator protein-1 complex and activating transcription factor-2. J Biol Chem 1999: 274: 6783– 6789. 65 Franchimont N, Wertz S, Malaise M. Interleukin-6: an osteotropic factor influencing bone formation? Bone, 2005: 37: 601– 606. 66 Friedenstein AJ. Precursor cells of mechanocytes. Int Rev Cytol 1976: 47: 327– 359. 67 Friedenstein AJ, Chailalhyan RK, Gerasimov UV. Bone marrow osteogenic stem cells: In vitro cultivation and transplantation in diffusion chambers. Cell Tissue Kinet 1987: 20: 263– 272. 68 Gabbitas B, Canalis E. Bone morphogenetic protein-2 inhibits the synthesis of insulin-like growth factor-binding protein-5 in bone cell cultures. Endocrinology 1995: 136: 2397– 2403. 69 Gabbitas B, Canalis E. Insulin-like growth factors sustain insulin-like growth factor-binding protein-5 expression in osteoblasts. Am J Physiol 1998: 275: E222– E228. 70 Gangji V, Rydziel S, Gabbitas B, Canalis E. Insulin-like growth factor II promoter expression in cultured rodent osteoblasts and adult rat bone. Endocrinology 1998: 139: 2287– 2292. 71 Garcia-Lopez S, Meikle MC, Villanueva RE, Montano L, Masso F, Ramirez-Amador V, Bojalil R. Mechanical deformation inhibits IL-10 and stimulates IL-12 production by mouse calvarial osteoblasts in vitro. Arch Oral Biol 2005: 50: 449– 452. 72 Gaur T, Lengner CJ, Hovhannisyan H, Bhat RA, Bodine PV, Komm BS, Javed A, Van Wijnen AJ, Stein JL, Stein GS, Lian JB. Canonical WNT signaling promotes osteogenesis by directly stimulating Runx2 gene expression. J Biol Chem 2005: 280: 33132– 33140. 73 Gestrelius S, Andersson C, Lidstrom D, Hammarstrom L, Somerman M. In vitro studies on periodontal ligament cells and enamel matrix derivative. J Clin Periodontol 1997: 24: 685– 692. 74 Giannobile WV, Somerman MJ. Growth and amelogenin-like factors in periodontal wound healing. A systematic review. Ann Periodontol 2003: 8: 193– 204. 75 Giannobile WV, Hernandez RA, Finkelman RD, Ryan S, Kiritsy CP, D'Andrea M, Lynch SE. Comparative effects of platelet-derived growth factor-BB and insulin-like growth factor-I, individually and in combination, on periodontal regeneration in Macaca fascicularis. J Periodontal Res 1996: 31: 301– 312. 76 Gilbert L, He X, Farmer P, Rubin J, Drissi H, Van Wijnen AJ, Lian JB, Stein GS, Nanes MS. Expression of the osteoblast differentiation factor RUNX2 (Cbfa1/AML3/Pebp2alpha A) is inhibited by tumor necrosis factor-alpha. J Biol Chem 2002: 277: 2695– 2701. 77 Gilbert LC, Rubin J, Nanes MS. The p55 TNF receptor mediates TNF inhibition of osteoblast differentiation independently of apoptosis. Am J Physiol Endocrinol Metab 2005: 288: E1011– E1018. 78 Giuliani N, Colla S, Morandi F, Lazzaretti M, Sala R, Bonomini S, Grano M, Colucci S, Svaldi M, Rizzoli V. Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation. Blood 2005: 106: 2472– 2483. 79 Glaser DL, Economides AN, Wang L, Liu X, Kimble RD, Fandl JP, Wilson JM, Stahl N, Kaplan FS, Shore EM. In vivo somatic cell gene transfer of an engineered Noggin mutein prevents BMP4-induced heterotopic ossification. J Bone Joint Surg Am 2003. 2332– 2342. 80 Gowen M, Mundy GR. Actions of recombinant interleukin 1, interleukin 2, and interferon-gamma on bone resorption in vitro. J Immunol 1986: 136: 2478– 2482. 81 Gowen M, Nedwin GE, Mundy GR. Preferential inhibition of cytokine-stimulated bone resorption by recombinant interferon gamma. J Bone Miner Res 1986: 1: 469– 474. 82 Gowen M, MacDonald BR, Russell RG. Actions of recombinant human gamma-interferon and tumor necrosis factor alpha on the proliferation and osteoblastic characteristics of human trabecular bone cells in vitro. Arthritis Rheum 1988: 31: 1500– 1507. 83 Graves DT, Valentin-Opran A, Delgado R, Valente AJ, Mundy G, Piche J. The potential role of platelet-derived growth factor as an autocrine or paracrine factor for human bone cells. Connect Tissue Res 1989: 23: 209– 218. 84 Grigoriades AE, Heersche JNM, Aubin JE. Differentiation of muscle, fat, cartilage and bone from progenitor cells present in a bone derived clonal cell population: Effects of dexamethasone. J Cell Biol 1988: 106: 2139– 2151. 85 Gronthos S, Graves SE, Ohta S, Simmons PJ. The STRO-1+ fraction of adult human bone marrow contains the osteogenic precursors. Blood 1994: 84: 4164– 4173. 86 Haase HR, Bartold PM. Enamel matrix derivative induces matrix synthesis by cultured human periodontal fibroblast cells. J Periodontol 2001: 72: 341– 348. 87 Hanazawa S, Ohmori Y, Amano S, Hirose K, Miyoshi T, Kumegawa M, Kitano S. Human purified interleukin-1 inhibits DNA synthesis and cell growth of osteoblastic cell line (MC3T3-E1), but enhances alkaline phosphatase activity in the cells. FEBS Letts 1986: 203: 279– 284. 88 Hannum CH, Wilcox CJ, Arend WP, Joslin FG, Dripps DJ, Heimdal PL, Armes LG, Sommer A, Eisenberg SP, Thompson RC. Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor. Nature 1990: 343: 336– 340. 89 Haynes DR, Atkins GJ, Loric M, Crotti TN, Geary SM, Findlay DM. Bidirectional signaling between stromal and hemopoietic cells regulates interleukin-1 expression during human osteoclast formation. Bone 1999: 25: 269– 278. 90 Hofbauer LC, Lacey DL, Dunstan CR, Spelsberg TC, Riggs BL, Khosla S. Interleukin-1beta and tumor necrosis factor-alpha, but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells. Bone 1999: 25: 255– 259. 91 Hoffmann HM, Catron KM, Van Wijnen AJ, McCabe LR, Lian JB, Stein GS, Stein JL. Transcriptional control of the tissue-specific, developmentally regulated osteocalcin gene requires a binding motif for the Msx family of homeodomain proteins. Proc Natl Acad Sci U S A 1994: 91: 12887– 12891. 92 Hogan B. Bone morphogenetic proteins in development. Curr Opin Genet Dev 1996: 6: 432– 438. 93 Holt I, Cooper RG, Denton J, Meager A, Hopkins SJ. Cytokine inter-relationships and their association with disease activity in arthritis. Br J Rheumatol 1992: 31: 725– 733. 94 Holt I, Davie MW, Marshall MJ. Osteoclasts are not the major source of interleukin-6 in mouse parietal bones. Bone 1996: 18: 221– 226. 95 Hong JH, Hwang ES, McManus MT, Amsterdam A, Tian Y, Kalmukova R, Mueller E, Benjamin T, Spiegelman BM, Sharp PA, Hopkins N, Yaffe MB. TAZ, a transcriptional modulator of mesenchymal stem cell differentiation. Science 2005: 309: 1074– 1078. 96 Hosokawa R, Kikuzaki K, Kimoto T, Matsuura T, Chiba D, Wadamoto M, Sato Y, Maeda M, Sano A, Akagawa Y. Controlled local application of basic fibroblast growth factor (FGF-2) accelerates the healing of GBR. An experimental study in beagle dogs. Clin Oral Implants Res 2000: 11: 345– 353. 97 Howell TH, Fiorellini JP, Paquette DW, Offenbacher S, Giannobile WV, Lynch SE. A phase I/II clinical trial to evaluate a combination of recombinant human platelet-derived growth factor-BB and recombinant human insulin-like growth factor-I in patients with periodontal disease. J Periodontol 1997: 68: 1186– 1193. 98 Hughes FJ, Aubin JE. Culture of cells of the osteoblast lineage. In: TR Arnett, B Henderson, editors. Methods in Bone Biology. London: Chapman Hall, 1998: 1– 49. 99 Hughes FJ, Howells GL. Interleukin-6 inhibits bone formation in vitro. Bone Miner 1993: 21: 21– 28. 100 Hughes FJ, Mc Culloch CAG. Quantification of chemotactic response of quiescent and proliferating fibroblasts in Boyden chambers by computer-assisted image analysis. J Histochem Cytochem 1991: 39: 243– 246. 101 Hughes FJ, Aubin JE, Heersche JNM. Differential chemotactic responses of different populations of fetal rat calvaria cells to platelet-derived growth factor and transforming growth factorβ. Bone Miner 1992: 19: 63– 73. 102 Hughes FJ, Collyer J, Stanfield M, Goodman SA. The effects of bone morphogenetic protein-2, -4 and -6 on differentiation of rat osteoblast cells in vitro. Endocrinology 1995: 136: 2671– 2677. 103 Hughes FJ, Buttery L, Hukkanen M, Polak JM. Regulation of osteoblast activity by nitric oxide. In: M Hukkanen, JM Polak, SPF Hughes, editors. Nitric Oxide in Bone and Joint Disease. Cambridge: Cambridge University Press, 1998: 105– 115. 104 Hughes FJ, Buttery LD, Hukkanen MV, O'Donnell A, Maclouf J, Polak JM. Cytokine-induced prostaglandin E2 synthesis and cyclooxygenase-2 activity are regulated both by a nitric oxide-dependent and -independent mechanism in rat osteoblasts in vitro. J Biol Chem 1999: 274: 1776– 1782. 105 Hukkanen M, Hughes F, Buttery L, Gross S, Evans T, Seddon S, Riveros-Moreno V, MacIntyre I, Polak J. Cytokine-stimulated expression of inducible nitric oxide synthase by mouse, rat and human osteoblast-like cell and its functional role in osteoblast metabolic activity. Endocrinology 1995: 136: 5445– 5453. 106 Hurley MM, Abreu C, Harrison JR, Lichtler AC, Raisz LG, Kream BE. Basic fibroblast growth factor inhibits type I collagen gene expression in osteoblastic MC3T3-E1 cells. J Biol Chem 1993: 268: 5588– 5593. 107 Hwa V, Oh Y, Rosenfeld RG. Insulin-like growth factor binding protein-3 and -5 are regulated by transforming growth factor-beta and retinoic acid in the human prostate adenocarcinoma cell line PC-3. Endocrine 1997: 6: 235– 242. 108 Iotsova V, Caamano J, Loy J, Yang Y, Lewin A, Bravo R. Osteopetrosis in mice lacking NF-kappaB1 and NF-kappaB2. Nat Med 1997: 3: 1285– 1289. 109 Iraburu MJ, Dominguez-Rosales JA, Fontana L, Auster A, Garcia-Trevijano ER, Covarrubias-Pinedo A, Rivas-Estilla AM, Greenwel P, Rojkind M. Tumor necrosis factor alpha downregulates expression of the alpha1(I) collagen gene in rat hepatic stellate cells through a p20C/EBPbeta- and C/EBPdelta-dependent mechanism. Hepatology 2000: 31: 1086– 1093. 110 Ishimi Y, Miyaura C, Jin CH, Akatsu T, Abe E, Nakamura Y, Yamaguchi A, Yoshiki S, Matsuda T, Hirano T, Kishimoto T, Suda T. IL-6 is produced by osteoblasts and induces bone resorption. J Immunol 1990: 145: 3297– 3303. 111 Janssens K, Ten Dijke P, Janssens S, Van Hul W. Transforming growth factor-beta1 to the bone. Endocr Rev 2005: 26: 743– 774. 112 Jensen SS, Broggini N, Weibrich G, Hjorting-Hansen E, Schenk R, Buser D. Bone regeneration in standardized bone defects with autografts or bone substitutes in combination with platelet concentrate: a histologic and histomorphometric study in the mandibles of minipigs. Int J Oral Maxillofac Implants 2005: 20: 703– 712. 113 Jin QM, Anusaksathien O, Webb SA, Rutherford RB, Giannobile WV. Gene therapy of bone morphogenetic protein for periodontal tissue engineering. J Periodontol 2003: 74: 202– 213. 114 Jin Q, Anusaksathien O, Webb SA, Printz MA, Giannobile WV. Engineering of tooth-supporting structures by delivery of PDGF gene therapy vectors. Mol Ther 2004: 9: 519– 526. 115 Jonk LJ, Itoh S, Heldin CH, Ten Dijke P, Kruijer W. Identification and functional characterization of a Smad binding element (SBE) in the JunB promoter that acts as a transforming growth factor-beta, activin, and bone morphogenetic protein-inducible enhancer. J Biol Chem 1998: 273: 21145– 21152. 116 Kahari VM, Chen YQ, Su MW, Ramirez F, Uitto J. Tumor necrosis factor-alpha and interferon-gamma suppress the activation of human type I collagen gene expression by transforming growth factor-beta 1. Evidence for two distinct mechanisms of inhibition at the transcriptional and posttranscriptional levels. J Clin Invest 1990: 86: 1489– 1495. 117 Kamimura D, Ishihara K, Hirano T. IL-6 signal transduction and its physiological roles: the signal orchestration model. Rev Physiol Biochem Pharmacol 2003: 149: 1– 38. 118 Kassai Y, Munne P, Hotta Y, Penttila E, Kavanagh K, Ohbayashi N, Takada S, Thesleff I, Jernvall J, Itoh N. Regulation of mammalian tooth cusp patterning by ectodin. Science 2005: 309: 2067– 2070. 119 Katagiri T, Yamaguchi A, Ikeda T, Yoshiki S, Wozney JM, Rosen V, Wang EA, Tanaka H, Omura S, Suda T. The non-osteogenic mouse pluripotent cell line, C3H10T1/2, is induced to differentiate into osteoblastic cells by recombinant human bone morphogenetic protein-2. Biochem Biophys Res Comm 1990: 172: 295– 299. 120 Kawaguchi H, Yavari R, Stover ML, Rowe DW, Raisz LG, Pilbeam CC. Measurement of interleukin-1 stimulated constitutive prostaglandin G/H synthase (cyclooxygenase) mRNA levels in osteoblastic MC3T3-E1 cells using competitive reverse transcriptase polymerase chain reaction. Endocrine Res 1994: 20: 219– 233. 121 Kawai S, Sugiura T. Characterization of human bone morphogenetic protein (BMP)-4 and -7 gene promoters: activation of BMP promoters by Gli, a sonic hedgehog mediator. Bone 2001: 29: 54– 61. 122 King GN. The importance of drug delivery to optimize the effects of bone morphogenetic proteins during periodontal regeneration. Curr Pharm Biotechnol 2001: 2: 131– 142. 123 King GN, King N, Cruchley AT, Wozney JM, Hughes FJ. Recombinant human bone morphogenetic protein-2 promotes wound healing in rat periodontal fenestration defects. J Dent Res 1997: 76: 1460– 1470. 124 King GN, King N, Hughes FJ. Effect of two delivery systems for recombinant human bone morphogenetic protein-2 on periodontal regeneration in vivo. J Periodontal Res 1998: 33: 226– 236. 125 Kinoshita A, Oda S, Takahashi K, Yokota S, Ishikawa I. Periodontal regeneration by application of recombinant human bone morphogenetic protein-2 to horizontal circumferential defects created by experimental periodontitis in beagle dogs. J Periodontol 1997: 68: 103– 109. 126 Kinto N, Iwamoto M, Enomoto-Iwamoto M, Noji S, Ohuchi H, Yoshioka H, Kataoka H, Wada Y, Yuhao G, Takahashi HE, Yoshiki S, Yamaguchi A. Fibroblasts expressing Sonic hedgehog induce osteoblast differentiation and ectopic bone formation. FEBS Lett 1997: 404: 319– 323. 127 Klein-Nulend J, Semeins CM, Ajubi NE, Nijweide PJ, Burger EH. Pulsating fluid flow increases nitric oxide (NO) synthesis by osteocytes but not periosteal fibroblasts – correlation with prostaglandin upregulation. Biochem Biophys Res Comm 1995: 217: 640– 648. 128 Knothe Tate ML, Steck R, Forwood M